deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01183481

Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

Sponsor: Merck Frosst Canada Ltd.

Conditions Nausea Vomiting
Interventions Aprepitant Granisetron Palliative radiation therapy
Updated 10 times since 2017 Last updated: Sep 27, 2019 Started: Jan 31, 2011 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was stopped due to inadequate accrual.

Other terminated trials from Merck Frosst Canada Ltd.

More terminations from Merck Frosst Canada Ltd.

Other Nausea trials with similar outcome

Browse all Nausea trials

Listed as NCT01183481, this PHASE2 trial focuses on Nausea and Vomiting and remains terminated or withdrawn. Sponsored by Merck Frosst Canada Ltd., it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Nov 2019 · 17 months · monthly snapshotTerminated~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Nov 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Jun 2018 — Nov 2019 [monthly]

    Terminated PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Frosst Canada Ltd.
  • Sunnybrook Health Sciences Centre
Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations